Evidence map›Paper›PMID 39153127›Full record

ArticleBreast cancer research and treatment2025

Prognostic and predictive impact of NOTCH1 in early breast cancer.

Julia Engel, Vanessa Wieder, Marcus Bauer, Sandy Kaufhold, Kathrin Stückrath, Jochen Wilke, Volker Hanf, Christoph Uleer, Tilmann Lantzsch, Susanne Peschel and 9 more

Erratum issued Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01592825 (PiA Trial), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01592825 unknown statusnot on this map

PiA Trial: a Cross-sectional, Multicenter, Consecutive Cohort Evaluating the Distribution of uPA/PAI-1 Versus St. Gallen Algorithm in >1000 Prospectively Included Patients

TypeobservationalSponsorMartin-Luther-Universität Halle-WittenbergRan2009 to 2021Enrolled1,000ConditionsBreast Cancer
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Julia EngelDepartment of Gynaecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Vanessa WiederDepartment of Gynaecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Marcus BauerInstitute of Pathology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Sandy KaufholdDepartment of Gynaecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Kathrin StückrathDepartment of Gynaecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Jochen WilkeOnkologische Gemeinschaftspraxis, Fürth, Germany.
Volker HanfDepartment of Obstetrics and Gynaecology, Klinikum Fürth, Nathanstift Fürth, Germany.
Christoph UleerGynäkologisch-Onkologische Praxis, Hildesheim, Germany.
Tilmann LantzschDepartment of Gynaecology, Hospital St. Elisabeth and St. Barbara, Halle (Saale), Germany.
Susanne PeschelDepartment of Gynaecology, St. Bernward Hospital, Hildesheim, Germany.
Jutta JohnDepartment of Gynaecology, Helios Hospital Hildesheim, Hildesheim, Germany.
Marleen PöhlerDepartment of Gynaecology, Asklepios Hospital Goslar, Goslar, Germany.
Edith WeigertInstitute of Pathology, Hospital Fürth, Fürth, Germany.
Karl-Friedrich BürrigInstitute of Pathology, Hildesheim, Germany.
Jörg BuchmannInstitute of Pathology, Hospital Martha-Maria, Halle (Saale), Germany.
Pablo SantosInstitute of Epidemiology, Biometry and Informatics, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Eva Johanna KantelhardtDepartment of Gynaecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Christoph Thomssen *Department of Gynaecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Martina Vetter *Department of Gynaecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany. martina.vetter@uk-halle.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSystemic therapy plays a major part in the cure of patients with early breast cancer (eBC). However, personalized treatment concepts are required to avoid potentially harmful overtreatment. Biomarkers are pivotal for individualized therapy. The Notch signalling pathway is widely considered as a suitable prognostic or predictive marker in eBC. This study aimed primarily at assessing the relationship between NOTCH1 mRNA expression levels and histopathological features of breast cancer tumors, as well as clinical characteristics of the correspondent eBC patients. As a secondary aim, we investigated the prognostic and predictive value of NOTCH1 by assessing possible associations between NOTCH1 mRNA expression and recurrence-free interval (RFI) and overall survival after five years of observation. PATIENTS AND

methodsThe relative NOTCH1 mRNA expression was determined in 414 tumour samples, using quantitative PCR in a prospective, multicenter cohort (Prognostic Assessment in Routine Application (PiA), 2009-2011, NCT01592825) of 1,270 female eBC patients.

resultsHigh NOTCH1 mRNA expression was detected in one-third of the tumours and was associated with negative hormone receptor status and high uPA/PAI-1 status. In addition, high NOTCH1 mRNA expression was found to be associated with more RFI related events (adjusted hazard ratio 2.1, 95% CI 1.077-4.118). Patients who received adjuvant chemotherapy and had high NOTCH1 mRNA expression in the tumour (n = 86) were three times more likely to have an RFI event (adjusted hazard ratio 3.1, 95% CI 1.321-7.245, p = 0.009).

conclusionIn this cohort, NOTCH1 mRNA expression had a prognostic and predictive impact. Tumours with high NOTCH1 mRNA expression may be less sensitive to cytotoxic treatment and downregulation of the Notch signalling pathway (e.g. by γ-secretase inhibitors) may be valuable for eBC therapy as an individualised treatment option.

Indexed as

Biomarkers, TumorBreast NeoplasmsReceptor, Notch1AdultAgedFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedNeoplasm StagingPrognosisRNA, MessengerBiomarkers, TumorNOTCH1 protein, humanReceptor, Notch1RNA, MessengerChemotherapy resistanceEarly breast cancerNotchPredictionPrognosis

Identifiers

PMID39153127
PMCPMC11785638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.